Treatment of hepatitis C in children with direct-acting antiviral drugs

Krestine Rosager Hansen; Jesper Kjærgaard; Helene Kvistgaard; Dorthe Grosen; Mette Holm; Jan Gerstoft; Sannie Nordly; Thora Wesenberg Helt; Vibeke Brix Christensen

doi:10.61409/V08230522

Treatment of hepatitis C in children with direct-acting antiviral drugs

Krestine Rosager Hansen, Jesper Kjærgaard, Helene Kvistgaard, Dorthe Grosen, Mette Holm, Jan Gerstoft, Sannie Nordly, Thora Wesenberg Helt, Vibeke Brix Christensen^*

^*Corresponding author af dette arbejde

Abstract

The primary purpose of treating chronic hepatitis C (HCV) is to prevent the development of liver fibrosis, cirrhosis, and cancer. In the last decade, direct-acting antiviral medicine (DAA) has been approved to treat children with HCV. This treatment has a higher efficacy, shorter duration, and milder side effects than the previously approved treatment. In this review, it is recommended to track down children who might be infected with HCV to enhance early treatment to prevent transmission of the virus and the possible complications.

Bidragets oversatte titel	Treatment of hepatitis C in children with direct-acting antiviral drugs
Originalsprog	Dansk
Artikelnummer	V08230522
Tidsskrift	Ugeskrift for Laeger
Vol/bind	186
Udgave nummer	1
ISSN	0041-5782
DOI	https://doi.org/10.61409/V08230522
Status	Udgivet - 1 jan. 2024

Emneord

Antiviral Agents/adverse effects
Child
Hepacivirus
Hepatitis C
Hepatitis C, Chronic/drug therapy
Humans
Liver Cirrhosis/complications

Adgang til dokumentet

10.61409/V08230522

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{bc0e01f82c2f48ac8538cfc79f75f43b,

title = "Treatment of hepatitis C in children with direct-acting antiviral drugs",

abstract = "The primary purpose of treating chronic hepatitis C (HCV) is to prevent the development of liver fibrosis, cirrhosis, and cancer. In the last decade, direct-acting antiviral medicine (DAA) has been approved to treat children with HCV. This treatment has a higher efficacy, shorter duration, and milder side effects than the previously approved treatment. In this review, it is recommended to track down children who might be infected with HCV to enhance early treatment to prevent transmission of the virus and the possible complications.",

keywords = "Antiviral Agents/adverse effects, Child, Hepacivirus, Hepatitis C, Hepatitis C, Chronic/drug therapy, Humans, Liver Cirrhosis/complications",

author = "Hansen, {Krestine Rosager} and Jesper Kj{\ae}rgaard and Helene Kvistgaard and Dorthe Grosen and Mette Holm and Jan Gerstoft and Sannie Nordly and Helt, {Thora Wesenberg} and Christensen, {Vibeke Brix}",

note = "Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.",

year = "2024",

month = jan,

day = "1",

doi = "10.61409/V08230522",

language = "Dansk",

volume = "186",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "1",

}

TY - JOUR

T1 - Treatment of hepatitis C in children with direct-acting antiviral drugs

AU - Hansen, Krestine Rosager

AU - Kjærgaard, Jesper

AU - Kvistgaard, Helene

AU - Grosen, Dorthe

AU - Holm, Mette

AU - Gerstoft, Jan

AU - Nordly, Sannie

AU - Helt, Thora Wesenberg

AU - Christensen, Vibeke Brix

N1 - Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

PY - 2024/1/1

Y1 - 2024/1/1

N2 - The primary purpose of treating chronic hepatitis C (HCV) is to prevent the development of liver fibrosis, cirrhosis, and cancer. In the last decade, direct-acting antiviral medicine (DAA) has been approved to treat children with HCV. This treatment has a higher efficacy, shorter duration, and milder side effects than the previously approved treatment. In this review, it is recommended to track down children who might be infected with HCV to enhance early treatment to prevent transmission of the virus and the possible complications.

AB - The primary purpose of treating chronic hepatitis C (HCV) is to prevent the development of liver fibrosis, cirrhosis, and cancer. In the last decade, direct-acting antiviral medicine (DAA) has been approved to treat children with HCV. This treatment has a higher efficacy, shorter duration, and milder side effects than the previously approved treatment. In this review, it is recommended to track down children who might be infected with HCV to enhance early treatment to prevent transmission of the virus and the possible complications.

KW - Antiviral Agents/adverse effects

KW - Child

KW - Hepacivirus

KW - Hepatitis C

KW - Hepatitis C, Chronic/drug therapy

KW - Humans

KW - Liver Cirrhosis/complications

UR - http://www.scopus.com/inward/record.url?scp=85182954862&partnerID=8YFLogxK

U2 - 10.61409/V08230522

DO - 10.61409/V08230522

M3 - Review

C2 - 38235776

SN - 0041-5782

VL - 186

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 1

M1 - V08230522

ER -

Treatment of hepatitis C in children with direct-acting antiviral drugs

Abstract

Emneord

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater